Centinel Spine, Inc. has completed the alpha release of its STALIF L no-profile, lateral lumbar integrated interbody device cleared by the U.S. Food and Drug Administration (FDA).
The device offers no-profile, compressive lag fixation with proprietary anti-backout technology and 12-degrees of lordosis as well as a large chamber for bone graft to support fusion, optimized fixation with easily placed self-drilling, self-tapping screws and a variety of cage sizes to match patient anatomy.
Centinel Spine, Inc. is a privately held spinal device company that began operations in August 2008 through the merger-acquisition of Raymedica LLC and Surgicraft LTD.
STALIF L lateral integrated inter body technology (Credit: Centinel Spine)
“Over the past year I have used the STALIF L to treat many of my patients in need of minimally invasive lateral lumbar reconstruction spine surgery,” Robert Kimber, MD, at the Gulfport, MS-based Performance Spine Institute, said. “STALIF L has the unique feature of compressive lag fixation, which assists me in ensuring that the bony endplates compress the device and bone graft, which I believe to be optimum in accordance with Wolff’s law.”
With the completion of its alpha release, the company will begin to release the STALIF L system to spine surgeons in the United States.
